ghk cu peptide fountain of youth GHK-Cu GHK-Cu Copper Peptide 0.5% (topical

Mov Disord 30:15911601

Together these data confirm the expectation that active 6-AH analogs can block dimerization and further that dimerization inhibitory potential of an analog translates, at least qualitatively, to its capacity to block HGF-dependent processes

useful for upper GI targeting Troches buccal absorption, limited evidence specific to BPC-157 Who oral delivery is best suited for: Leaky gut / intestinal permeability Inflammatory bowel disease (IBD, Crohn's, ulcerative colitis) NSAID-induced gastric damage or ulcers Irritable bowel syndrome (IBS) General GI maintenance alongside other therapies Patients who cannot or will not self-inject Practical considerations: Oral bioavailability is lower for systemic goals do not expect injection-equivalent tendon or joint results Dosing protocols typically require three to ten times the injectable dose to achieve comparable GI effects Product quality varies widely in the oral supplement market sourcing from a licensed compounding pharmacy is essential Nasal BPC-157: Emerging Option, Limited Evidence Nasal BPC-157 is the third delivery route and the least established

Rotate injection sites to prevent lipohypertrophy, which is the buildup of fatty tissue from repeated injections in the same location